303 related articles for article (PubMed ID: 29973218)
1. Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis.
Zubeldia-Plazaola A; Recalde-Percaz L; Moragas N; Alcaraz M; Chen X; Mancino M; Fernández-Nogueira P; Prats de Puig M; Guzman F; Noguera-Castells A; López-Plana A; Enreig E; Carbó N; Almendro V; Gascón P; Bragado P; Fuster G
Breast Cancer Res; 2018 Jul; 20(1):65. PubMed ID: 29973218
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
[TBL] [Abstract][Full Text] [Related]
3. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function.
Sarper M; Allen MD; Gomm J; Haywood L; Decock J; Thirkettle S; Ustaoglu A; Sarker SJ; Marshall J; Edwards DR; Jones JL
Breast Cancer Res; 2017 Mar; 19(1):33. PubMed ID: 28330493
[TBL] [Abstract][Full Text] [Related]
4. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
9. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
11. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
Sameni M; Cavallo-Medved D; Franco OE; Chalasani A; Ji K; Aggarwal N; Anbalagan A; Chen X; Mattingly RR; Hayward SW; Sloane BF
Breast Cancer Res; 2017 May; 19(1):56. PubMed ID: 28506312
[TBL] [Abstract][Full Text] [Related]
12. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence.
Allen MD; Thomas GJ; Clark S; Dawoud MM; Vallath S; Payne SJ; Gomm JJ; Dreger SA; Dickinson S; Edwards DR; Pennington CJ; Sestak I; Cuzick J; Marshall JF; Hart IR; Jones JL
Clin Cancer Res; 2014 Jan; 20(2):344-57. PubMed ID: 24150233
[TBL] [Abstract][Full Text] [Related]
13. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.
Duivenvoorden HM; Rautela J; Edgington-Mitchell LE; Spurling A; Greening DW; Nowell CJ; Molloy TJ; Robbins E; Brockwell NK; Lee CS; Chen M; Holliday A; Selinger CI; Hu M; Britt KL; Stroud DA; Bogyo M; Möller A; Polyak K; Sloane BF; O'Toole SA; Parker BS
J Pathol; 2017 Dec; 243(4):496-509. PubMed ID: 29086922
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
[TBL] [Abstract][Full Text] [Related]
15. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
16. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
17. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
[TBL] [Abstract][Full Text] [Related]
18. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
Zeng Y; Gao W; Chen X; Shen K
Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
[TBL] [Abstract][Full Text] [Related]
20. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.
Johnson CE; Gorringe KL; Thompson ER; Opeskin K; Boyle SE; Wang Y; Hill P; Mann GB; Campbell IG
Breast Cancer Res Treat; 2012 Jun; 133(3):889-98. PubMed ID: 22052326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
